[
  {
    "ts": "2025-10-24T15:08:50+00:00",
    "headline": "Can Biogen’s (BIIB) Immunology Pipeline Moves Reshape Its Competitive Edge in Autoimmune Disease?",
    "summary": "Biogen and partner UCB recently announced upcoming presentations at the American College of Rheumatology 2025 conference highlighting positive Phase 3 data for dapirolizumab pegol in treating systemic lupus erythematosus (SLE), supported by efficacy across multiple endpoints and promising safety data, especially in women of childbearing age. This follows a series of pipeline enhancements for Biogen in immunology and rare diseases, including a new licensing agreement with Vanqua Bio for a...",
    "url": "https://finance.yahoo.com/news/biogen-biib-immunology-pipeline-moves-150850231.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "0d3343cf-0e21-3d70-ac32-85f22c80bc86",
      "content": {
        "id": "0d3343cf-0e21-3d70-ac32-85f22c80bc86",
        "contentType": "STORY",
        "title": "Can Biogen’s (BIIB) Immunology Pipeline Moves Reshape Its Competitive Edge in Autoimmune Disease?",
        "description": "",
        "summary": "Biogen and partner UCB recently announced upcoming presentations at the American College of Rheumatology 2025 conference highlighting positive Phase 3 data for dapirolizumab pegol in treating systemic lupus erythematosus (SLE), supported by efficacy across multiple endpoints and promising safety data, especially in women of childbearing age. This follows a series of pipeline enhancements for Biogen in immunology and rare diseases, including a new licensing agreement with Vanqua Bio for a...",
        "pubDate": "2025-10-24T15:08:50Z",
        "displayTime": "2025-10-24T15:08:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-immunology-pipeline-moves-150850231.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-biib-immunology-pipeline-moves-150850231.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-24T14:58:00+00:00",
    "headline": "Biogen licenses a possible immune drug from OrbiMed-backed biotech",
    "summary": "The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.",
    "url": "https://www.biopharmadive.com/news/biogen-vanqua-deal-rights-licensing-drug-immune-C5aR1/803770/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "92cda956-f215-3b77-9281-b0890da2c05e",
      "content": {
        "id": "92cda956-f215-3b77-9281-b0890da2c05e",
        "contentType": "STORY",
        "title": "Biogen licenses a possible immune drug from OrbiMed-backed biotech",
        "description": "",
        "summary": "The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.",
        "pubDate": "2025-10-24T14:58:00Z",
        "displayTime": "2025-10-24T14:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/d540900dfeca05c4e916670bf3cce9f7",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wx3rE.9wl4ShzTP7GuSpyA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/d540900dfeca05c4e916670bf3cce9f7.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pH1Ru4NmtB2PTC74KQ6_WA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/d540900dfeca05c4e916670bf3cce9f7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/biogen-vanqua-deal-rights-licensing-drug-immune-C5aR1/803770/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-licenses-possible-immune-drug-145800405.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-24T14:33:00+00:00",
    "headline": "Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key",
    "summary": "Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.",
    "url": "https://finance.yahoo.com/news/biogen-beat-q3-earnings-leqembi-143300083.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "72f6f722-0805-3d32-b98a-97e7ed4d6f4b",
      "content": {
        "id": "72f6f722-0805-3d32-b98a-97e7ed4d6f4b",
        "contentType": "STORY",
        "title": "Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key",
        "description": "",
        "summary": "Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.",
        "pubDate": "2025-10-24T14:33:00Z",
        "displayTime": "2025-10-24T14:33:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9ba18c9e2c8fffeabdd247f567de5466",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.5Q_kyoqtcpsM1l1uvN2bQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9ba18c9e2c8fffeabdd247f567de5466.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KBUfPU_diptiGFZTYziQbg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9ba18c9e2c8fffeabdd247f567de5466.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-beat-q3-earnings-leqembi-143300083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-beat-q3-earnings-leqembi-143300083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-24T11:30:00+00:00",
    "headline": "Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio",
    "summary": "The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by advancing a proven immune mechanism with the potential to address a",
    "url": "https://finance.yahoo.com/news/biogen-licenses-oral-c5ar1-antagonist-113000085.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "bd0f99fe-357f-33be-a504-90abf3a68446",
      "content": {
        "id": "bd0f99fe-357f-33be-a504-90abf3a68446",
        "contentType": "STORY",
        "title": "Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio",
        "description": "",
        "summary": "The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by advancing a proven immune mechanism with the potential to address a",
        "pubDate": "2025-10-24T11:30:00Z",
        "displayTime": "2025-10-24T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-licenses-oral-c5ar1-antagonist-113000085.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-licenses-oral-c5ar1-antagonist-113000085.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-24T04:45:09+00:00",
    "headline": "3 Profitable Stocks We Steer Clear Of",
    "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, \"Your margin is my opportunity\".",
    "url": "https://finance.yahoo.com/news/3-profitable-stocks-steer-clear-044509820.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "7c6d4361-c9a7-345e-aa38-d8739557b833",
      "content": {
        "id": "7c6d4361-c9a7-345e-aa38-d8739557b833",
        "contentType": "STORY",
        "title": "3 Profitable Stocks We Steer Clear Of",
        "description": "",
        "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, \"Your margin is my opportunity\".",
        "pubDate": "2025-10-24T04:45:09Z",
        "displayTime": "2025-10-24T04:45:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/bda28095de95c3c98e3f51fd963ca401",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VICR Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R7erKI43eUFuH.LFhZO.3w--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/bda28095de95c3c98e3f51fd963ca401.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m8hJbLJ_Av3gcEf4W4sWGg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/bda28095de95c3c98e3f51fd963ca401.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-profitable-stocks-steer-clear-044509820.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-profitable-stocks-steer-clear-044509820.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KMT"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "VICR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]